Serina Therapeutics Inc (SER)
Serina Therapeutics, Inc. is a biotechnology company listed on the NYSE under the symbol SER. The company focuses on developing therapies for neurological diseases and pain. Its lead candidate, SER 252, is a POZ-apomorphine conjugate being studied in preclinical development for advanced Parkinson’s disease. Serina also develops POZ-lipids, which are designed as a non-immunogenic alternative to PEG-lipids in lipid nanoparticle systems. Another program, SER 214, is a POZ conjugate of rotigotine for early Parkinson’s disease and restless leg syndrome and has completed a phase 1a clinical trial. In addition, the company is working on applying its POZ technology to lipid nanoparticle-delivered RNA vaccines for infectious diseases. Serina Therapeutics was founded in 2006 and is based in Huntsville, Alabama.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-SER
|
$2.57
|
11.2% Upside
|
Fair
|
$9.50
|
311.3% Upside
|
Bargain
|
Weak
|
0.0%
|
November 18, 2026
|
3.1x
|
58.675 M
|
39.405 M
|
6.0%
|
43.9%
|
-1.5
|
88.6%
|
